Harm Reduction Through Community Engagement Act of 2025

Bill Number

H.R. 5844

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-10-28: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Last Updated

2025-11-26T15:59:26Z

AI-Generated Summary

Purpose

The Harm Reduction Through Community Engagement Act of 2025 aims to update federal rules for registering opioid treatment programs (OTPs) under the Controlled Substances Act. It seeks to boost input from local communities in the approval and operation of these programs while ensuring they focus on serving patients who genuinely need treatment for opioid addiction, such as through maintenance or detoxification services.

Key Provisions

• Registration Criteria for OTPs: Practitioners applying to dispense narcotic drugs for opioid treatment must meet new standards, including:
• Demonstrating how the program will address local community effects.
• Avoiding locations within one-half mile of day care centers, schools, learning centers, playgrounds, or other drug treatment facilities (including supervised injection sites).
• Providing evidence of patient need in the area.
• Promoting telehealth (remote medical consultations) to reduce in-person visits.
• Appointing a community liaison to build ties with local officials, law enforcement, and nonprofit social service groups.
• Using or creating a customer relationship management system (a tool for tracking service requests) to monitor drug-related issues in the community.
• Reporting data to the Secretary of Health and Human Services (HHS) on patient treatment outcomes, including long-term addiction recovery rates and telehealth effectiveness.
• Community Impact Requirements: OTPs must:
• Conduct outreach to notify and involve community groups, such as boards, tenant associations, health providers, and nonprofits focused on opioid prevention.
• Create a neighborhood engagement plan detailing interactions with stakeholders like homeowners, schools, businesses, and emergency services.
• Form a community advisory board with volunteers representing local views.
• Develop a community relations plan to reduce negative effects, such as loitering or public drug use, including procedures for resolving complaints and addressing quality-of-life issues like discarded needles.
• Reporting to Congress: The HHS Secretary must submit an annual report starting one year after enactment, covering treatment data, best practices for community involvement, and policy suggestions to support ongoing engagement.

Significant Changes to Existing Law

This bill amends Section 303(h) of the Controlled Substances Act (21 U.S.C. 823(h)), which governs registration for practitioners providing opioid maintenance or detoxification treatment. Key updates include:

• Expanding the list of qualifications for approval, adding community-focused and operational requirements (e.g., location buffers, telehealth promotion, and data reporting) that were not previously mandated.
• Introducing a new subsection on community impact assessment, requiring structured outreach, planning, and advisory boards—shifting from a primarily clinical focus to one that incorporates local input.
• Adding a congressional reporting mandate, which creates ongoing oversight not present in the original law.

These changes apply to both new registrations and renewals, making community engagement a core condition for operating legally.

Potential Impacts

• On Government Agencies: The HHS Secretary gains new responsibilities for reviewing applications, issuing guidance, and preparing annual reports, potentially increasing administrative workload and costs. Local governments may benefit from data-sharing tools for tracking drug issues.
• On Citizens and Communities: Residents near proposed OTPs get more say through outreach and advisory boards, which could reduce conflicts (e.g., "not in my backyard" opposition) but might delay program openings. Patients could see improved access via telehealth and better-targeted services, though location rules might limit options in some areas.
• On International Relations: Minimal direct impact, as this is a domestic regulatory change focused on U.S. opioid treatment.

Main Stakeholders Affected

• Opioid Treatment Programs and Practitioners: Face stricter registration and operational rules, requiring more planning and reporting to maintain federal approval.
• Local Communities and Residents: Gain influence through advisory boards and engagement plans, affecting where and how programs operate.
• Patients with Opioid Use Disorder: Benefit from needs-based justifications and telehealth emphasis, potentially leading to more effective, accessible treatment.
• Local Governments, Law Enforcement, and Nonprofits: Involved via liaisons, data systems, and outreach, enabling better coordination on drug-related community issues.
• Congress and HHS: Responsible for oversight, reporting, and policy recommendations to refine the framework.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens regulatory oversight of OTPs under the Controlled Substances Act by tying registration to community welfare, which could lead to more litigation over "patient need" justifications or location decisions if disputes arise. It promotes harm reduction strategies (e.g., telehealth and engagement) without altering core drug scheduling or enforcement powers.
• Constitutional: No apparent conflicts; the changes respect due process by requiring evidence-based approvals and community input, without infringing on free speech or property rights. It aligns with federal authority over controlled substances.
• Political: Encourages bipartisan support for opioid crisis response by balancing treatment expansion with community protections, potentially reducing local opposition to programs. However, it may spark debates over implementation burdens on providers versus benefits for public health.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Espaillat, Adriano [D-NY-13]

Recent Actions

• 2025-10-28: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2025-10-28: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2025-10-28: Introduced in House
• 2025-10-28: Introduced in House

Bill Versions

• Harm Reduction Through Community Engagement Act of 2025 — issued 2025-10-28 — PDF (7 pages)